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448* Development of medicines for children with CF under the new
European paediatric regulation
I. Eichler1, E. Sala Soriano1. 1European Medicines Agency, London, United
Kingdom
The European Paediatric Regulation entered into force in 2007 to promote research
into the development of medicines for children and to increase the availability
of drugs for paediatric use. Under this law companies are obliged to conduct
studies in children under the age of 18 in accordance with an agreed Paediatric
Investigation Plan (PIP) unless a formal waiver has been agreed. A Paediatric Com-
mittee (PDCO), including patient representatives, was established at the European
Medicines Agency (EMA). It is tasked to evaluate PIPs proposed by industry. Since
2007 the PDCO assessed ten PIPs related to CF: 5 were agreed by the PDCO, with
enrolment of approx. 3500 CF patients of all age subsets including neonates, 1 is still
being reviewed (antibiotics 3, CFTR modulator 1, other 2). Four PIP applications
were withdrawn by the applicants (2 due to substantial changes to the development
plan requested by the PDCO). To avoid unnecessary repetition of trials, paediatric
development is addressed globally by close cooperation between EMA and FDA.
The PDCO has identiﬁed areas where more research is needed: clinical trial
methodology, validation of endpoints, use of modelling and simulation. These gaps
in knowledge necessitate close collaboration between academia, the ECFS and the
PDCO. Academia may contribute by provision of expertise to PDCO in the PIP
reviewing process, membership of the European paediatric network created under
the coordination of EMA to facilitate research into paediatric medicines. Closer
cooperation between academia, industry, and regulators is required to consider both
scientiﬁc and regulatory requirements in the design of drug trials for children with
CF.
449 Inﬂuenza vaccination coverage in adult cystic ﬁbrosis
D. Wat1, H. Barker1, A. Floto1, S. Henman1, A. Lyons1, C. Murphy1, C. Haworth1.
1Papworth Hospital, Adult Cystic Fibrosis Unit, Cambridge, United Kingdom
Background: The Department of Health in the UK recommends inﬂuenza vaccina-
tion to people of clinical risk groups including patient with CF. Inﬂuenza infection
can lead to signiﬁcant morbidity and mortality in CF patients and vaccination
remains the most effective measure in preventing this illness. There has been
evidence to show that inﬂuenza vaccination in CF can prevent its subsequent
acquisition [1].
Aims: To evaluate the inﬂuenza vaccine uptake rate for the 2008−09 season in our
CF centre and the factors associated with non-adherence.
Methods: Retrospective questionnaire was given to all patients attended the CF
outpatient department and CF unit between June and September 2009.
Results: 174 patients participated. 131 (75%) patients were vaccinated; 41 (24%)
were not (10 patients forgot, 4 were scared of needles, 4 were worried of side-
effects, 6 were too unwell and 6 previously did not ﬁnd vaccination effective; other
reasons for not receiving vaccination include failure to make appointment with GP;
patients did not feel they require vaccination; not reminded about vaccination and
vaccination not offered.) 2 (1%) could not remember if they were vaccinated.
Discussion: The vaccination coverage in this group of patient is much higher than
the overall uptake rate in the clinical risk groups in England (75% vs 47.1%).
However, the uptake rate may be further enhanced by providing reminders and
patient education. We plan to re-evaluate the uptake rate next year after carrying
out the above actions. The recent Swine ﬂu pandemic may also indirectly heighten
patient’s future perception of seasonal ﬂu vaccination.
Reference(s)
[1] Wat D et al. J Cyst Fibros 2008 Jan; 7(1): 85−8.
450 Clinical status of adolescent CF patients before and after
transition from paediatric to adult services
M. Desai1, M. Tabberner1, J.L. Whitehouse2. 1Birmingham Children’s Hospital,
Department of Respiratory Medicine, Birmingham, United Kingdom; 2Heart of
England NHS Foundation Trust, Birmingham, United Kingdom
Aim: Anecdotal reports suggest that the clinical status of CF adolescents dete-
riorates markedly around the time of transition from paediatric to adult services,
raising questions about the appropriate timing of transfer of care.
Methods: A retrospective case note review of adolescents transferring between
August 2005 and February 2008 directly from the paediatric to adult centre in
Birmingham, UK was conducted to inform this discussion. Demographic, lung
function, nutritional and treatment data were collected at 3 time points: 1 year
before, at transition and 1 year after.
Results: Data from 17 patients (6F:11M) were collected. Mean age at transition
was 16.5 yrs. 14 were DF058:DF508, 3 were compound heterozygotes with 2 known
mutations. Mean weight was 60.1 kg (range 44.9–98.7 kg), BMI 21.3 (range 17.6–
27.0), mean FEV1 92% (range 49–127%). There was no overall change in weight,
BMI or FEV1 in the group as a whole. However some individual patients showed
dramatic declines or improvements in nutrition or lung function. Change in BMI
ranged between −3.41 and +4.22; change in FEV1 ranged between −14% predicted
and +10% predicted. All had been infected with Pseudomonas aeruginosa before
transition and 3 also with Staphylococcus aureus. New infections identiﬁed after
transition include 2 with Mycobacterium abscessus. One started insulin after
transition and 3 patients had their oral steroid dose reduced/stopped.
Conclusions: There is no consistent pattern of change in clinical status in this small
number of patients. However it is important to investigate the reasons why some
did better and some deteriorated post-transition with close co-operation between
the 2 units.
451 Tobacco smoke exposure and effectiveness of a smoking
cessation program in cystic ﬁbrosis patients and their relatives
M.D. Pastor-Vivero1, E. Martı´nez-Carrasco1, P. Monde´jar-Lo´pez1, M.T. Lo´pez-
Ferna´ndez2, J.A. Ortega-Garcı´a2, M. Sa´nchez-Solı´s1. 1Arrixaca Children’s
Universitary Hospital, Pediatric Pulmonology and Cystic Fibrosis Unit, Murcia,
Spain; 2Arrixaca Children’s Universitary Hospital, Pediatric Environmental Health
Unit, Murcia, Spain
Aim: To study the prevalence and features of tobacco smoke exposure (TSE) and
to assess a smoking cessation program (SCP) in cystic ﬁbrosis patients (PCF) and
their relatives.
Methods: Phase I : A prospective study was performed in order to assess the level of
TSE in CFP and relatives who attend the CF Unit of Murcia (Spain). Data (level of
active smoking and secondhand exposure at home, work and entertainment places)
on CFP were collected by means of a phone questionnaire. Furthermore, urinary
cotinine concentration (UC) was measured in CFP and relatives living in the same
household.
Phase II : A one-year SCP which included phone interventions and motivational
interviewing was designed and implemented by a trained nurse.
Results: Phase I : 97 CFP and their families were contacted. 45 relatives and 8 CFP
(14%) were active smokers at the moment of the survey. 56% of non-smokers
reported being exposed to secondhand smoke and only 57% of CFP lived in smoke-
free homes. UC was measured in 69 CFP (49% >10 ng/ml). There was a high
correlation between UC and TSE level as rated by the phone questionnaire (r = 0.77;
p< 0.0001).
Phase II : Telephone intervention was performed in all smokers. 9 of them (3 CFP)
accepted a face-to-face behavioral therapy. After a one-year follow-up period,
13 individuals (4 CFP) attempted smoking cessation and 10 (2 CFP) reduced the
number of cigarettes. Finally, and after a demonstration by cooximetry, 6 (11.3%)
achieved the aim; including 2 CFP (25%).
Conclusions: Although the prevalence of TSE in our CFP is high (14%), it is lower
than in the general population of our Region (34%). This SCP was useful in 25%
of smokers CFP and in 9% of their relatives.
